SCHEMBL31137266

SCHEMBL31137266

CNCc1ccc(OCC(F)(F)F)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CARM1 Q86X55 1/20 0.48
▸ PRMT6 Q96LA8 1/20 0.48
▸ LOXL2 Q9Y4K0 1/20 0.46
▸ ALDH1A1 P00352 2/20 0.44
▸ NPC1 O15118 1/20 0.42
▸ RAB9A P51151 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ MEN1 O00255 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ PAX8 Q06710 1/20 0.41
▸ MAPT P10636 2/20 0.41
▸ KDM4E B2RXH2 2/20 0.41
▸ CYP3A4 P08684 1/20 0.41
▸ CACNA1B Q00975 2/20 0.40
▸ PIK3CD O00329 1/20 0.40
▸ PIK3CA P42336 1/20 0.40
▸ PIK3CB P42338 1/20 0.40
▸ PRMT1 Q99873 1/20 0.40
▸ CYP2C9 P11712 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8292121 0.80 MRGPRX4 (0.48) CARM1PRMT6ALDH1A1MAPTKDM4E
SCHEMBL498377 0.79 ALDH1A1 (0.56) ALDH1A1NPC1RAB9ASMN1; SMN2MEN1
SCHEMBL10271093 0.79 SMN1; SMN2 (0.45) CARM1PRMT6ALDH1A1NPC1RAB9A
SCHEMBL12015662 0.77 MEN1 (0.50) ALDH1A1NPC1RAB9ASMN1; SMN2MEN1
SCHEMBL178527 0.77 EPHX2 (0.51) CARM1PRMT6LOXL2ALDH1A1SMN1; SMN2
SCHEMBL3004004 0.76 NQO1 (0.61) LOXL2ALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL4550724 0.76 L3MBTL1 (0.49) MAPTCYP2C9CYP2C19CYP1A2CACNA1G
Hydrochloric Acid SCHEMBL28806796 0.76 MEN1 (0.49) ALDH1A1NPC1RAB9ASMN1; SMN2MEN1
SCHEMBL21033436 0.76 ALDH1A1 (0.45) CARM1PRMT6ALDH1A1NPC1RAB9A
Hydrochloric Acid SCHEMBL3397561 0.76 EPHX2 (0.50) CARM1PRMT6ALDH1A1SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388585-A1 PRMT5 INHIBITORS AND USES THEREOF GILEAD SCIENCES INC (US) 2025-12-25 — — US disclosed
US-12448388-B2 PRMT5 inhibitors and uses thereof GILEAD SCIENCES, INC. (US) 2025-10-21 — — US disclosed
US-20240376110-A1 PRMT5 INHIBITORS AND USES THEREOF GILEAD SCIENCES, INC. 2024-11-14 — — US disclosed
WO-2024220917-A1 PRMT5 INHIBITORS AND USES THEREOF GILEAD SCIENCES, INC. (US) 2024-10-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250388585-A1 PRMT5 INHIBITORS AND USES THEREOF PRMT1, PRMT5, PRMT6 CARM1 8/4885PRMT6 3/4885LOXL2 3829/4885
US-20240376110-A1 PRMT5 INHIBITORS AND USES THEREOF PRMT5, PRMT1, PRMT9 CARM1 10/4885PRMT6 4/4885LOXL2 3694/4885
US-12448388-B2 PRMT5 inhibitors and uses thereof PRMT5, PRMT1, PRMT9 CARM1 10/4885PRMT6 4/4885LOXL2 3694/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback